TTM
−$105.14M
YoY change
-22.2%
5Y CAGR
—
Peak year (2019)
−$14.52M
Cumulative EBITDA
−$599.58M
EBITDA history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: −$99.31M
EBITDA growth chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: -22.2%
EBITDA history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | −$99.31M | -22.2% | +$28.29M | ||
| 2024 | −$127.59M | +28.6% | −$28.40M | ||
| 2023 | −$99.19M | -6.9% | +$7.32M | ||
| 2022 | −$106.51M | +86.7% | −$49.47M | ||
| 2021 | −$57.05M | +13.3% | −$6.70M | ||
| 2020 | −$50.35M | +246.8% | −$35.83M | ||
| 2019 | −$14.52M | — | — |
- 2025−$99.31M-22.2%
- 2024−$127.59M+28.6%
- 2023−$99.19M-6.9%
- 2022−$106.51M+86.7%
- 2021−$57.05M+13.3%
- 2020−$50.35M+246.8%
- 2019−$14.52M—
EBITDA values are taken from Tango Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Tango Therapeutics (TNGX)
According to Tango Therapeutics's latest reported financial statements, the company's current EBITDA (TTM) is −$105.14M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Tango Therapeutics (TNGX) most recent annual EBITDA stands at −$99.31M (2025) – declined 22.2% year-over-year.
2019 marks the peak EBITDA at −$14.52M, with the historical low of −$127.59M recorded in 2024.
Tango Therapeutics EBITDA by Year
Tango Therapeutics EBITDA 2025: −$99.31M
Tango Therapeutics posted EBITDA of −$99.31M in 2025, declined 22.2% below 2024.
Tango Therapeutics EBITDA 2024: −$127.59M
In 2024, Tango Therapeutics reported EBITDA of −$127.59M, grew 28.6% from 2023. This figure represents the lowest annual value in the available history.
Tango Therapeutics EBITDA 2023: −$99.19M
Tango Therapeutics EBITDA in 2023 was −$99.19M, declined 6.9% below 2022.
Tango Therapeutics EBITDA 2022: −$106.51M
2022's EBITDA for Tango Therapeutics came in at −$106.51M, surged 86.7% from 2021.
Tango Therapeutics EBITDA 2021: −$57.05M
Tango Therapeutics EBITDA in 2021 was −$57.05M.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by EBITDA
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation